Home/Pipeline/AAVOT: T Cell Immunotherapy

AAVOT: T Cell Immunotherapy

Solid Tumors

PreclinicalActive

Key Facts

Indication

Solid Tumors

Phase

Preclinical

Status

Active

Company

Aavocyte

About Aavocyte

Aavocyte is a private, preclinical-stage biotech founded in 2019 and based in San Diego, CA. The company is developing the AAVOT platform, which leverages rAAV vectors to engineer precisely targeted T cell immunotherapies for solid tumors, positioning itself in the competitive but high-potential cell therapy space. As a platform company, it is likely pre-revenue and focused on R&D, with its lead programs still in early development. Its success hinges on validating its novel, non-gene therapy approach to cell engineering and translating it into effective clinical candidates.

View full company profile

Therapeutic Areas

Oncology

Other Solid Tumors Drugs

Drug	Company	Phase	Status
APVO603	Aptevo Therapeutics	Preclinical	Active
APVO711	Aptevo Therapeutics	Preclinical	Active
Platform-derived Immunotherapy	GenCirq	Pre-clinical	Active
DM001	Domabio	Phase 1	Active (IND cleared in US and China)
DM002	Domabio	Phase 1	Active (IND cleared in US)
DM005	Domabio	Phase 1	Active (IND cleared in US, Australia, and China; first patient dosed in US)
SP-2-225	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
SP-1-161	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
CAR-T Solid Tumor Program	Carina Biotech	Phase 1/2a	Active
HBM1020	Harbour BioMed	Phase 1	Active (Global)
HBM7022	Harbour BioMed	Phase 1	Out-Licensed
HBM9033	Harbour BioMed	Discovery	Out-Licensed